Literature DB >> 33910824

Endosialin (CD248) Expression in Fibromas and Soft-tissue Fibrosarcomas in Dogs.

Magdalena Marzec1, Małgorzata Kandefer-Gola2, Izabela Janus2, Joanna Bubak2, Marcin Nowak2.   

Abstract

BACKGROUND/AIM: Endosialin is present in human fibrosarcoma neoplastic cells. This study aimed to analyse the expression of selected cellular proteins found in fibrosarcomas and soft-tissue fibroids in dogs.
MATERIALS AND METHODS: A total of 71 skin tumours obtained from dogs were used. The samples included 31 fibromas and 40 fibrosarcomas. Histopathological evaluation was performed according to World Health Organization guidelines. Immunohistochemistry was performed with anti-endosialin, Ki-67, cyclo-oxygenase 2 and vimentin antibodies and assessed using the semi-quantitative scale.
RESULTS: Endosialin expression was observed in 82.5% of fibrosarcomas and in 35% of fibromas. A significant positive correlation was found between the expression of endosialin in fibrosarcoma neoplastic cells and the degree of histological malignancy and the expression of the Ki-67 and cyclo-oxygenase 2 antigen. Expression of vimentin confirmed mesenchymal origin of this tumours.
CONCLUSION: The results of our research suggest that endosialin is involved in the carcinogenesis of fibrosarcoma in dogs. Copyright
© 2021, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

Entities:  

Keywords:  Endosialin (CD248); dog; fibroma; fibrosarcoma

Mesh:

Year:  2021        PMID: 33910824      PMCID: PMC8193292          DOI: 10.21873/invivo.12399

Source DB:  PubMed          Journal:  In Vivo        ISSN: 0258-851X            Impact factor:   2.406


  21 in total

1.  Effects of the cyclooxygenase inhibitor, piroxicam, on tumor response, apoptosis, and angiogenesis in a canine model of human invasive urinary bladder cancer.

Authors:  Sulma I Mohammed; Peter F Bennett; Bruce A Craig; Nita W Glickman; Anthony J Mutsaers; Paul W Snyder; William R Widmer; Amalia E DeGortari; Patty L Bonney; Deborah W Knapp
Journal:  Cancer Res       Date:  2002-01-15       Impact factor: 12.701

2.  Evaluation of information presented within soft tissue sarcoma histopathology reports in the United States: 2012-2015.

Authors:  A M Livaccari; L E Selmic; J K Reagan; E A Driskell; M T Cray; L M Lamoureux; L D Garrett
Journal:  Vet Comp Oncol       Date:  2018-03-25       Impact factor: 2.613

Review 3.  Cyclooxygenase-2: a novel target for cancer chemotherapy?

Authors:  W Dempke; C Rie; A Grothey; H J Schmoll
Journal:  J Cancer Res Clin Oncol       Date:  2001-07       Impact factor: 4.553

Review 4.  Cellular proliferation in tumors: a review of methods, interpretation, and clinical applications.

Authors:  B R Madewell
Journal:  J Vet Intern Med       Date:  2001 Jul-Aug       Impact factor: 3.333

5.  Association of argyrophilic nucleolar organizing regions, Ki-67, and proliferating cell nuclear antigen scores with histologic grade and survival in dogs with soft tissue sarcomas: 60 cases (1996-2002).

Authors:  Susan N Ettinger; Timothy J Scase; Karen T Oberthaler; Diane M Craft; Josephine A McKnight; Nicole F Leibman; Sarah C Charney; Philip J Bergman
Journal:  J Am Vet Med Assoc       Date:  2006-04-01       Impact factor: 1.936

6.  Expression of E-cadherin, beta-catenin and Ki-67 antigen and their reciprocal correlations in fibrosarcomas of soft tissues in dogs.

Authors:  Marcin Nowak; Janusz A Madej; Piotr Dziegiel
Journal:  In Vivo       Date:  2007 Sep-Oct       Impact factor: 2.155

7.  Fibrosarcomas at presumed sites of injection in dogs: characteristics and comparison with non-vaccination site fibrosarcomas and feline post-vaccinal fibrosarcomas.

Authors:  M Vascellari; E Melchiotti; M A Bozza; F Mutinelli
Journal:  J Vet Med A Physiol Pathol Clin Med       Date:  2003-08

Review 8.  Canine oral fibrosarcoma: Changes in prognosis over the last 30 years?

Authors:  M Martano; S Iussich; E Morello; P Buracco
Journal:  Vet J       Date:  2018-09-05       Impact factor: 2.688

9.  Oncolytic peptide LTX-315 induces an immune-mediated abscopal effect in a rat sarcoma model.

Authors:  Janne Nestvold; Meng-Yu Wang; Ketil A Camilio; Severin Zinöcker; Torunn Elisabeth Tjelle; Alf Lindberg; Bengt Erik Haug; Gunnar Kvalheim; Baldur Sveinbjørnsson; Øystein Rekdal
Journal:  Oncoimmunology       Date:  2017-06-16       Impact factor: 8.110

Review 10.  CD248: A therapeutic target in cancer and fibrotic diseases.

Authors:  Beverly A Teicher
Journal:  Oncotarget       Date:  2019-01-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.